Neuraltus was founded in 2005 by Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco, Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine, and Ari Azhir, PhD. Based on the scientific research of Dr. McGrath, Neuraltus is developing a drug to treat ALS. In 2007, Neuraltus began a collaboration with the Parkinson’s Institute of Sunnyvale, California that has led to its work developing a drug to treat dyskinesias in patients with Parkinson’s disease. Neuraltus is also working with physicians at the Hospital for Sick Children in Toronto on a treatment for lysosomal storage disorders.